



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis and characterization of novel natural product-Gd(III) MRI contrast agent conjugates

Eleni K. Efthimiadou^a, Maria E. Katsarou^a, Michael Fardis^b, Christos Zikos^a, Emmanuel N. Pitsinos^{a,*}, Athanasios Kazantzis^a, Leondios Leondiadis^c, Marina Sagnou^d, Dionisios Vourloumis^{a,*}

^aChemical Biology Program, Institute of Physical Chemistry, NCSR 'DEMOKRITOS', PO Box 60228, GR-153 10 Aghia, Paraskevi, Greece

^bInstitute of Material Sciences, NCSR 'DEMOKRITOS', Greece

^cMass Spectrometry and Dioxin Analysis, Institute of Radiodiagnosics and Radiopharmaceuticals, NCSR 'DEMOKRITOS', Greece

^dNMR Studies of Biomolecules and Pharmaceuticals, Institute of Biology, NCSR 'D', Greece

ARTICLE INFO

Article history:

Received 19 September 2008

Revised 7 October 2008

Accepted 7 October 2008

Available online 11 October 2008

Keywords:

MRI contrast agents

Gd(III) complexes

Tubulin

Thyroxine binding globulin

ABSTRACT

Several novel gadolinium chelates conjugated with paclitaxel, colchicine and thyroxine have been prepared as MRI contrast agents targeted to tubulin and thyroxine-binding globulin, respectively.

© 2008 Elsevier Ltd. All rights reserved.

Magnetic resonance imaging (MRI) is a non-invasive imaging technique, extensively used in the clinic, which allows for high-definition pictures of a whole-organism to be obtained over extended periods of time. The technique is often enhanced by the use of contrast agents (CAs). Among them, paramagnetic gadolinium chelates hold a prominent position.¹ In general, these agents are injected systemically and serve to passively and non-specifically enhance the signal by increasing the longitudinal relaxation rate ($1/T_1$) of surrounding water molecules. Furthermore, binding to a macromolecule increases concentration and retention of the CA at the binding site and affords an increase in relaxivity, resulting from a decrease in the rotational correlation time (τ_r).² As the contrast gained is still limited, relatively high doses of CA are required for sufficient contrast enhancement. There are two major ways to decrease the unwanted and potentially toxic high CA administered dose: (i) by employing new Gd(III) complexes endowed with much higher relaxivities; (ii) by improvement of the biodistribution of CAs. Recently, the development of 'smart' CAs that will accumulate at a specific tissue, or sense a particular biological event, has attracted considerable attention.³ Thus, gadolinium chelates have been tagged with various targeting elements, including natural products. Conjugates with peptides,⁴ steroids,⁵ carbohydrates,⁶ and an anticancer anthracycline⁷ have been pre-

pared, with the aim to guide the gadolinium label towards the biological target of the natural product, to increase the lipophilicity of the CA or to facilitate pharmacokinetic studies. In this context, it should be noted that the delivery of sufficient quantity of the paramagnetic label and/or the ability of the conjugates to cross cellular membranes is a challenge.⁸

In the frame of a research program aiming at the development of novel, targeted MRI contrast agents, we have designed conjugates of paclitaxel, colchicine and thyroxine with the known, and approved for clinical use as MRI-CA, Gd(III) complexes with diethylenetriaminepentaacetic acid bis-methyl amide ([Gd(DTPA-BMA)], OmniscanTM) and/or 1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid ([Gd-DOTA], DotaremTM) (Fig. 1). We report herein




Figure 1. Structures of some clinically used Gd-chelates.

* Corresponding authors. Tel.: +30 2106503624; fax: +30 2106511766.

E-mail address: vourloumis@chem.demokritos.gr (D. Vourloumis).


the synthesis of the targeted conjugates along with their relevant toxicities and magnetic properties.

Microtubules are long stiff polymers formed from molecules of tubulin (heterodimer of α - and β -form). They are critical for internal cell organelle trafficking and vital for mitotic spindle formation during cell division.⁹ Paclitaxel, a natural product clinically used for the therapy of several carcinoma lines (TaxolTM), binds to microtubules with high affinity ($K_d \sim 10^{-8}$ M) and a maximum stoichiometry of one ligand per heterodimer, promoting tubulin polymerization.¹⁰ On the other hand, each molecule of the alkaloid colchicine, which is clinically utilized for the treatment of autoimmune-inflammatory diseases and gout, binds tightly to one tubulin molecule and prevents its polymerization.¹¹ The obvious complementarity of the two has inspired the synthesis of several paclitaxel¹² and colchicine derivatives,¹¹ to study intracellular drug distribution and their interference with the, otherwise, finely balanced assembly/disassembly dynamics of microtubules. Based on the above mentioned literature evidence, paclitaxel and colchicine conjugates are expected to target the CA to tissues of high tubulin content, such as sites of actively propagating tumours. In addition, they may facilitate the prescription of these clinically used drugs on a personalized medicine basis, or the identification of any possible, previously undetected, preference in their distribution in the body.

Thyroxine (T_4) is one of the hormones produced by the thyroid gland. Only a minute fraction ($<0.03\%$) of T_4 circulating in the blood is free and thus available to tissues. Most of it is present in the biologically inactive state, bound to transport proteins, mainly thyroxine-binding globulin (TBG) but also transthyretin (TTR) and albumin (HSA).¹³ These proteins sequester one (TBG, TTR) or several (HSA) hormone molecules. Although albumin is present in higher concentration (40,000 mg/L vs 16 mg/L of TBG), TBG has the highest affinity ($K_a = 1 \times 10^{10} \text{ M}^{-1}$) and carries most (75%) of the serum's T_4 .¹⁴ Binding of T_4 by these proteins safeguards the body from the effects of abrupt fluctuations in hormone secretion. Interestingly, in the case of TBG, selective hormone release at sites of inflammation has also been reported.¹⁵ Consequently, thyroxine conjugates are expected to exhibit increased retention time in the blood-stream, compared with the untagged CA, and thus improved performance in cardiovascular MRI. Furthermore, T_4 conjugates might allow selective MRI of inflammation sites.

For the synthesis of colchicine-Gd(III) conjugates the natural product **1** was deacetylated, as previously described, to yield amine **2** in 40% overall yield (Scheme 1).^{11b} In order to address the possibility of the gadolinium-complex interfering with binding of the natural product to its biological target, a short, 4-atom linker, was introduced through a coupling reaction with **3** mediated by DIC, followed by liberation of the corresponding amine through acidic treatment. In parallel, complexation of GdCl_3 with commercially available *p*-SCN-Bn-DOTA was accomplished under carefully controlled pH conditions,^{5b} producing complexed isothiocyanate **6** in 75% yield, spectroscopically identical to the one reported previously.^{5b} Thus, no further attempts for the determination of Gd(III)-concentration in the complex were performed. Mixing of the two colchicine analogues **2** and **4** with **6** in DMSO, in the presence of triethylamine, furnished the corresponding conjugates **7** and **8** in 60% yield, after HPLC purification.

Similarly, taking advantage of the differential reactivity of the hydroxyls at 2'- and 7-positions, paclitaxel was selectively protected in the form of a Cbz-carbonate (Scheme 2).^{12a} Introduction of an attachment linker was performed by DCC mediated coupling of protected γ - or δ -aminoacids to furnish, upon subsequent simultaneous removal of the Cbz protecting groups by catalytic hydrogenation, **12** or **13** in 95% yield. Attachment of the complexed isothiocyanate **6** was performed as before, yielding conjugates **14** and **15** in 60% and 65% yield, respectively.



Scheme 1. Synthesis of colchicine derivatives **7** and **8**. Reagents and conditions: (a) $(\text{Boc})_2\text{O}$ (5.5 equiv), DMAP (1.1 equiv), Et_3N (11.0 equiv), 12 h, 0°C , 60%; (b) NaOMe (3.5 equiv), MeOH (0.20 M), 30 min, 0°C , 75%; (c) 20% TFA, CH_2Cl_2 , pentamethylbenzene (4.0 equiv), 8 h, 40°C , 90%; (d) **3** (2.1 equiv), DIC (1.5 equiv), DMAP (0.01 equiv), 3 h, $0 \rightarrow 25^\circ\text{C}$, 86%; (e) 20% TFA, CH_2Cl_2 , pentamethylbenzene (4.0 equiv), 8 h, 40°C , 90%; (f) GdCl_3 (1.0 equiv), phosphate buffer, pH 6.5, 30 min, 75%; (g) **6**, Et_3N (1.5 equiv), DMSO (0.05 M), 24 h, 25°C , 60% for **7** and **8**. Boc = *t*-butoxycarbonyl; DIC = *N,N'*-diisopropylcarbodiimide; DMAP = 4-(dimethylamino)pyridine; TFA = trifluoroacetic acid; DMSO = dimethyl sulfoxide.

For the synthesis of thyroxine conjugates, peracetylation of the natural product was required to allow the selective coupling of the carboxyl-moiety with an appropriately protected diamine-linker. Subsequent saponification of the acetate ester followed by removal of the Boc protective group, furnished amine **16** in 75% overall yield. Attachment of the Gd(III) complex **6** was performed as before, yielding conjugate **17** in quantitative yield. Reaction of **16** with commercially available dianhydride **18** produced, after complexation with GdCl_3 in pyridine, dimeric compound **19** in 65% overall yield (Scheme 3).

The effect of compounds **7**, **8**, **14**, **15**, **17**, and **19** on the viability of two human cancer cell lines, HeLa and MCF-7 was assessed, using the MTT assay.¹⁶ Complex **6** was also tested in various concentrations (in the μM range). The IC_{50} values were estimated from the % viability versus concentration plots, using sigmoidal fit and are presented in Table 1. In general, no significant cytotoxicity

Download English Version:

<https://daneshyari.com/en/article/1364339>

Download Persian Version:

<https://daneshyari.com/article/1364339>

[Daneshyari.com](https://daneshyari.com)